Royalty Report: Drugs, Drug Discovery, Proteins – Collection: 310414

License Grant

The Company was assigned an Option by a Third Party and would like to exercise its right under the Option Agreement to take an Exclusive License to the technology covered in the Option Agreement

University grants an exclusive right and license to practice under the Licensed Patents and Licensed Technology to make, have made, develop, promote, market, import, export, distribute, offer for sale and sell and otherwise use the Licensed Products in the Field of Use within the Licensed Territory during the Term of this Agreement, with rights to Sublicense any and all of such rights to Sublicensees in accordance with the terms of this Agreement.

License Property

Licensor is a research university,  These products are related to patents filed by University directed to methods using the active ingredient in the anti-cancer agent Imatinib, as an anti-infective. These compounds were designed to inhibit c-Abl in patients for a therapeutic purpose. These patents formed the starting point for Licensees RAMP drug discovery program.

The Patents are
Compositions and Methods of Use of Tyrosine Kinase Inhibitors to Treat Infections caused by HIV-1, by Mycobacterium Tuberculosis, and by Polyoma and Related Viruses;  Development of Novel Tyrosine Kinase Inhibitors for Treating Infectious Diseases; Use of Tyrosine Kinase Inhibitors to Treat Mycobacterium Tuberculosis and Related Infections; and, Use of Tyrosine Kinase Inhibitors as Therapeutics for Polyomavirus Infections.

Option Invention shall mean any patentable addition, enhancement, modification, development, alteration, technical advance to Licensed Patents or Licensed Technology to the extent any such improvement is owned or controlled by University.

These products are related to patents filed by Licensor directed to methods using the active ingredient in the anti-cancer agent Imatinib, as an anti-infective.

Field of Use

The Field of Use shall include the prevention, diagnosis, treatment or control of human and animal infectious diseases or related conditions other than Tuberculosis.

The patent rights related to the application of Imatinib or a series of novel analogs for the treatment of infections caused by both viruses and bacteria that utilize c-Abl protein kinase to reproduce in human hosts.

This License grants is related to the application of Imatinib or a series of novel analogs for the treatment of infections caused by both viruses and bacteria that utilize c-Abl protein kinase to reproduce in human hosts.

Licensee is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain.

License Grant

Licensor grants to the Israeli Licensee the worldwide right and exclusive license to make, have made, use, lease and sell the Licensed Products and to practice the Licensed Processes for the Field of Use to the end of the term for which the Patent Rights are granted, unless sooner terminated as provided in this Agreement.

License Property

The patents are for Short peptides which selectively modulate the activity of protein tyrosine kinases, and, Short Peptides which selectively modulate the activity of serine/threonine kinases.

KinAce platform represents one of the first practical uses of the genomics database to systematically generate drug candidates that target protein kinases. We use computer programs to analyze genomic data that then enables us to create compounds that aim to regulate kinases.  Protein kinases play a key role in the way cells communicate. When protein kinases give an inappropriate signal, the result is often a disease or other unwanted medical condition. Our KinAce platform uses a proprietary algorithm to identify unique regulatory regions within each kinase.

Field of Use

The Field of Use shall mean the diagnosis, prevention or treatment of any and all diseases or conditions in humans or animals.

License Grant

For the Research License, The Canadian Licensor grants to the Licensee of Japan a co-exclusive, solely with respect to Licensor, right and license, under the Licensor Intellectual Property, to conduct Licensees responsibilities under the Research Program in the Field in the Territory during the Selection Period.

For the Development and Commercialization License, Licensor grants an exclusive, even as to Licensor, right and license, under the Licensor Intellectual Property, to Develop Selected Compounds into Licensed Products intended for use in the Field in the Territory, and make and have made, use, offer for sale, sell, have sold and import Selected Compounds and Licensed Products in the Field in the Territory.

For the Grant of Certain Jointly Developed Methyl Gene Collaboration Intellectual Property for use Outside the Field, Licensor grants a perpetual, irrevocable, non-exclusive right and license to use, solely outside the Field, Licensor Collaboration Intellectual Property that is Formulation Technology or Know-How that directly relates to the physicochemical property pharmacokinetics/pharmacodynamics relationship in ocular tissue, and is jointly developed, conceived or created by or on behalf of Licensor and/or its Affiliates, on the one hand, and by or on behalf of Licensee and/or its Affiliates, on the other hand.

License Property

The patents are titled
Inhibitors of VEOF Receptor and HOF Receptor;
Inhibitors of Protein Tyrosine Kinase Activity;
Kinase Inhibitors and Uses Thereof;
Processes and Intermediates for Preparing Fused;
Heterocyclic Kinase Inhibitors;
Inhibitors of Protein Tyrosine Kinase Activity;
Inhibitors of Kinase Activity.

A Compound is a molecule that is a small molecule that is a small molecule tyrosine kinase inhibitor as its main mechanism of action, and any salts, hydrates, solvates, polymorphs, free base, isomers, prodrugs, metabolites and/or liposomal or other formulations thereof or other compositions consisting of such molecule non-covalently bonded with other moieties, but excluding any derivative of such molecule in which the chemical structure of such molecule is altered.

Field of Use

Field means the prevention, treatment, control, mitigation or palliation in humans of diseases, disorders and other medical conditions caused by choroidal angiogenesis, including, without limitation, age-related macular degeneration, and diabetic retinopathy and retinal edema; in each case using local delivery of the active pharmaceutical agents to the eye.  For the avoidance of doubt, “local delivery” shall include, without limitation, topical, intravitreal, periorbital, intraocular and other local administration to the eye, the ocular and/or periocular tissues and spaces, including, without limitation, via delivery devices, but in any event, subject to Section 3.6, shall not include systemic delivery, including, without limitation, parenteral or sublingual delivery or delivery through a patch.  The Field shall expressly exclude the prevention, treatment, control, mitigation or palliation of any Indications other than above (e.g., treatment of cancer, including, without limitation, neoplasia and other pre-cancerous conditions and ocular cancer, is excluded).

License Grant

The University grants to Licensee a world-wide, non-transferable license under its rights in and to the Patent Rights, only in the Field of Use, to make, have made, use, sell, offer to sell and import Patent Products, and to use and practice the Licensed Methods and Patent Rights, including for purposes of identifying, creating, discovering, developing and commercializing Identified Products, in the Field of Use.

The University also grants to Licensee the right to sublicense to third parties.

License Property

Therapeutic Licensed Product means a Licensed Product that is used to prevent, treat or cure one or more diseases and/or conditions of human beings or animals.

Diagnostic Licensed Product means a Licensed Product that is used as a human or veterinary diagnostic and/or prognostic.

Identified Product means a Product that has prophylactic, therapeutic, diagnostic or prognostic value and is identified, created, discovered or developed as a result of practicing the Licensed Method, use of Patent Products, or use or practicing of any Product, process or method anywhere in the world covered by a Valid Claim within the Patent Rights in any one country.

Certain inventions, generally characterized as Nucleic Acids Encoding Neural Axon Outgrowth Modulators, Netrins, Netrin Receptors, Semaphorin Receptors, Human Netrin~1, Promoters of Neural Regeneration and Compositions for Promoting Nerve Regeneration.

Patents include small molecule, Ligands and Receptors.

Field of Use

Field of Use means any and all uses, including for or relating to human or veterinary prophylaxes; therapeutics, diagnostics and prognostics, including without limitation use in assaying or screening for therapeutic, diagnostic and prognostic targets, validation of therapeutic, diagnostic and prognostic targets, and use for drug discovery purposes such as the identification of new chemical entities, but specifically excluding Research Reagent Use.